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1 
Introduction 
In England, government policy causes pharmacists to be 
financially rewarded for issuing the least costly version of a 
medication. For example, Panadol (brand name) may be issued as 
a generic medication (paracetamol) at a fraction of the price. When 
people receive their tablet / capsule medicines from their 
pharmacist, the brand and so the appearance (colour, size, shape) 
can be vastly different to those dispensed following their previous 
prescription despite having the same active ingredient. This is 
often due to a lack of standardisation practice required amongst 
manufacturers. Drugs are made to British Pharmacopoeia 
standards but these do not specify colour, size and shape. The 
Directive 2001/83/EC of the European Parliament stated that 
medicines had to be of 'essential similarity' but that does not 
include appearance. 
This ‘generic prescribing’ does enable the pharmacist to supply 
any licensed generic product. This ensures market forces operate 
and a medicine of the required quality, purchased at the least cost 
can be supplied. However, there are some community pharmacies 
that purchase generic products on a ‘spot market’ basis and ask 
wholesalers to send them the ‘cheapest’ product whenever they 
order, even when the cheapest product is cheaper by one or two 
pence from the previous supply. 
Furthermore, some changes in appearance of tablets and 
capsules are due to ‘parallel imports’. These are medications that 
are supplied by parallel importers from Europe which can be re-
sold to pharmacies in the UK so long as labelling in English is 
attached.  
Whatever the cause of the changes in appearance of tablets and 
capsules, substantive anecdotal evidence that the changes 
presented challenges to many older people was presented to the 
research team by older people in Rochdale Borough. Members of 
the Rochdale User Carer Action Forum raised concerns that the 
changes in appearance of medicines had contributed to people 
they knew ending up being admitted to hospital due to poor 
medicine control. They provided examples of older people 
becoming confused or upset by unexpected changes in the 
appearance of their prescription medicines. Older people were 
known to have omitted their medicines for several days until clarity 
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was gained, or for example where a tablet had become smaller, 
doses were doubled ‘just in case’.  
Email conversations took place between the project lead and the 
European Commission and National Patient Safety Agency. It was 
concluded that whilst these agencies had themselves heard 
anecdotal evidence of a problem concerning appearance of 
medicines, there would need to be a substantial body of evidence 
of significant risk in order to influence the EU and National 
Governments to change EU directives concerning medicines.  
The research team was approached to see if it could acquire 
funding to investigate the problem further on behalf of Rochdale 
User Carer Action Forum members. Funding for the survey 
described here was gained and six older people volunteered to be 
study advisors to inform the design and conduct of the study. 
 
Study Approach 
 
Aim 
 
The aim of the study was to develop a questionnaire in partnership 
with older people to survey older people’s views of fluctuating 
tablet medication appearance and the impact on their medication-
taking practices. 
Older People’s Involvement 
Older people have prompted this study and have been involved as 
advisors since its outset. Rochdale User Carer Action Forum 
members have informed the study design also. The advisors have 
had an impact on the questions to be asked and wording of these 
as well as specifying the target population as being respondents 
aged 50 years and above. Advisors were clear that response rate 
would be optimised by return of questionnaires to an Age Concern 
office rather than a University of Salford address as first proposed. 
Advisors provided access to the Rochdale User Carer Action 
Forum to gain first hand anecdotal accounts of older people to 
inform study design. Individual advisors’ own networks e.g. 
Pensioners’ Association, Over 50s Group, permitted a wider reach 
to gain the views of older people to inform the study focus as well 
as providing direct access to audiences to disseminate findings to. 
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Advisors helped design the pilot survey and then administered it to 
their contacts. 
Sample 
The survey was sent to 2000 older people aged 50 years or over 
residing in Greater Manchester and currently prescribed three or 
more medicines in tablet/capsule form.  
Questionnaire 
An eight-question questionnaire was devised in partnership with 
older people from the study advisory group. This is a self-
completion, mostly tick-box design with room for comments.  
Data Collection 
Of all of the Primary Care Trusts in Greater Manchester who were 
invited to take part, six agreed to work with us.  All GP practices 
within them were asked to assist in forwarding a questionnaire to 
patients who met the study criteria. From those six PCTs, a total of 
ten GP practices agreed to assist. The PCTs were Heywood, 
Middleton & Rochdale PCT; Stockport PCT; Ashton, Leigh & 
Wigan PCT; Oldham PCT; Salford PCT; and Tameside & Glossop 
PCT.  
Each GP practice forwarded 200 questionnaires to eligible 
respondents and returns of completed questionnaires ceased by 
the end of March 2008.   
Ethical Approvals 
Usual university, NHS research ethics and research governance 
approvals were gained.  
 
Results  
 
As not all questions were answered by all people returning the 
questionnaire, the number of respondents for each question is 
made clear by putting the number (‘n’) in brackets e.g. (n=540).  
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A. Response Rate 
 
Out of 2000 questionnaires sent, 581 responses were received, 
which is a 29% return rate.  
B. Personal data 
Gender (n = 562) 
 
254 (45.2%) were male  
308 (54.8%) were female 
Age (n = 569) 
 
100 people (17.6%) were aged 50-64 
251 people (44.1%) were aged 65-74 
183 people (32.2%) were aged 75-84 
35 people (6.2%) were aged 85+ 
 
Ethnicity (n = 567) 
 
Ethnicity was described by respondents as: 
 
527 (92.9%) White 
14 (2.5%) White, Irish 
2 (0.4%) White, other 
1 (0.2%) Indian 
5 (0.9%) Pakistani 
13 (2.3%) Asian, other 
2 (0.4%) Black Caribbean 
3 (0.5%) Other 
 
C. Changes in tablet appearance 
 
The questionnaire asked whether respondents had experienced 
changes in appearance of their tablet medicines (other than due to 
changes in dose or drug).  
 
Of the respondents answering this question, 368 people (63.3%) 
had experienced a change in the appearance of their tablet 
medicines. In contrast, 213 people (36.7%) had not experienced a 
change in the appearance of their tablet medicine.  
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Of those who had noticed a change, there was no significant 
difference amongst men and women’s responses. Neither were 
there any significant differences in responses from across age 
categories. However, respondents who identified themselves as 
‘White’ tended to notice changes occurring to their prescribed 
tablet medicines significantly more than people in other ethnic 
groups.  
 
D. Nature of changes  
 
Experiences of specific changes to the appearance of tablet 
medicines were then sought. Respondents were asked to report all 
of the changes that they had experienced. 
 
 
Specific ways the appearance of prescribed tablet medicines 
changed 
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These findings suggest that the most common change to the 
appearance of prescribed tablet medicines is found in the 
packaging, followed by the colour of the tablets, then the shape 
and size of tablets. 
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E. Advice seeking  
 
When asked if the changes to their prescribed tablet medicines 
had led them to seek advice, of the 347 people who replied, 257 
(74.1%) indicated that they had not sought advice and 90 (25.9%) 
indicated that they had sought advice. The advice seeking group 
did so from their pharmacist, doctor or a family member.  
 
Of those who had sought advice, the number of men was 32 
(20.9%) and the number of women was 53 (28.5%). There were no 
significant differences across age groups or ethnic groups as to 
who sought advice.  
 
F. Medication borrowing practices 
 
Of the 411 people who replied to the question about borrowing 
prescribed medicines, 15 people (3.6%) stated that they had used 
prescribed tablet medicines from other sources than their GP, 
including neighbours, friends and family members, whereas 396 
(96.4%) stated that they had not borrowed prescribed tablet 
medicines from sources other than their GP.  
 
 
Analysis of Comments 
 
 
There was space in the questionnaire for respondents to write 
comments or give further details and a summary is given here.  
 
A. Changes in appearance of tablet medicines  
 
The results of the survey indicated large numbers of respondents 
who had experienced changes in the colour (n=227), shape 
(n=180) and size (n=146) of their tablet medicines. 
 
Respondents were invited to give examples of these changes 
which are summarised here. 
 
Colour changes tended to be complete changes e.g. from white to 
orange although some were more subtle changes such as brown 
to pale brown. Others were dual-coloured whereby one colour 
changed e.g. from purple and white to pink and white. Some 
changed from a single colour to dual colours e.g. from white to 
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orange and white and vice versa. Others changed several shades 
e.g. white to pale orange to dark orange. Sometimes colours 
changed back and forth between original colour and new colour. 
Respondents noted that changes sometimes depended on which 
Dispensing Pharmacy they attended and that it was not always 
possible to go to the same place.  
 
Size changes related mostly to tablets becoming smaller or larger 
but retaining the same colour. For a few, other changes were in 
both size and colour simultaneously. Sometimes size changed 
back and forth between original size and new size. 
 
Shape changes were mostly from round to oval shape and vice 
verse. Some changes were from round to rectangular shape. One 
was from diamond to round shape and for another the change was 
from triangle to oval shape. A further change was from a blue 
triangle to a white round shape. 
 
Packaging changes generally concerned moves from coloured 
boxes (manufacturer’s own) to plain dispensing boxes. Boxes also 
changed in size. Several reported changes concerned the move 
from calendar packaging to non-calendar packaging and those 
with days of the week marked on to those without such markings. 
Further changes included bottle to blister pack, foil packaging 
becoming very thick and from foil wrapper to bottle. Occasional 
mention was made of tablets being transferred into dosette boxes 
which generally helped although there was a single mention that 
information leaflets concerning the medicines were absent. 
Another isolated comment was that larger blister packs had days 
indicated on them but no days were indicated on small packs of 
the same drug.  
 
B. Effects of changes in appearance of tablet medicines 
 
Respondents were asked how they had been affected by changes 
in prescribed tablet medicine appearance.  
 
a) Personal effects 
? Having to check medicine name and strength 
? That they change colour, size and shape all the time and I 
find this extremely confusing 
? Have given much cause for concern 
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? I wonder if much smaller tablets are as good. Do they 
contain as much medication?  
? Sometimes not taken until found out if OK to do so, so as not 
to take wrong ones. I do wonder if these contain other 
ingredients 
? As I get older I can see difficulties with this 
? I find changes in the size and colour of tablets very confusing 
? I have to double check they are the same prescription 
? I also have to be careful as my husband takes a tablet that 
can look similar for a different condition 
? Foreign language days of the week are confusing 
? Being partially sighted I find it confusing 
? I think the survey is very good as the change of tablet (shape 
and colour) can cause confusion 
? As I have been given wrong tablets by the pharmacist on two 
separate occasions, changing the colours of the 
tablets/capsules only add to the anxiety 
? Very confusing for people taking 13 a day after stroke 
? Confused. Loss of confidence in being able to take 
medication on my own 
? Gives rise to doubts as to correct medicine until verified 
? Uncertainty and unease about taking the tablets before 
seeking the advice of the pharmacist 
? Annoyance and concern for the tablet takers who suffer poor 
eyesight 
? Concern that it was not as good as my previous one which I 
found to be satisfactory 
? I dispense weekly to daily containers … I regularly have to 
tell her of colour or shape change. My wife gets confused 
and accuses me of giving her wrong medicines 
? Frustration!!! 
? Did not feel I could take the tablets with as much confidence 
? Colour change made me feel that the medication was not as 
effective in helping the relief of my pain 
? The colour change upset me when the chemist changed 
supply 
? Anxiety - wondering if the tablets are incorrect and given by 
mistake 
? I rely a lot on others and changes like this make me feel 
even more reliant 
? When changes are made in size, colour and shape for no 
apparent reason it really annoys me 
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Large numbers of respondents expressed no problem with 
changes in medication appearance or said that they were fine 
once they had sought advice. Many others said they had 
experienced confusion. 
 
b) Way take medicines 
? Sometimes I have to cut them in half 
? Some medicines don’t have days of the week on them and 
this can lead to confusion whether you have taken them 
? I like to take tablets in order and usually go by colour, size 
and shape and then I do not forget to take any 
? I find a packet better because it enables me to write on it to 
remind me what the medication is for and I can colour it as a 
code for myself as to when to take it e.g. morning or night 
? I have to check the boxes because they change so much. It’s 
so easy until you get used to the new packaging to get mixed 
up. You get used to them and then they change them again 
? I put my tablets in a 7 day pill box. Changes in shape and 
colour make it difficult to check at a glance 
? Wife has to issue them 
? Need help in taking medication when packaging changes but 
once adjusted I am able to cope 
? I re-think the medicine only to have to change back the 
following month 
? I do think about the changes but I haven’t been to seek 
advice 
? I usually remove all tablets from their foil containers on 
receipt and transfer them to empty, clearly labelled bottles 
? Taken the wrong tablets - my husband’s - instead of mine 
because the colours are the same. Also taken my night-time 
in the morning because they look the same 
 
c) General comments 
? It would be less confusing if the same brands were 
prescribed each month when I collect tablets from the 
chemist 
? Just wish they would stop changing the tablets and leave as 
they are 
? Is it possible for 2/3 different medicines to be combined in 
one tablet to ease arthritic fingers fumbling with small blister 
packs? 
? I find it confusing when I have to get my prescription from a 
different pharmacy than usual as the tablets can then 
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change. Sometimes I get a different brand from the same 
pharmacy  
? Just didn’t want to take them without assurance that they 
were the same tablets 
? All tablets from different manufacturers should be 
standardised  
? The writing on all medicines could be bigger 
? I would feel more comfortable with the same brands all the 
time 
? I am not confident that anyone is protecting us from 
standards existing in say Romania. I would like reassurance 
that we are not getting cheap substitutes 
? I guess why the drugs change so much, they say the right 
name, but it’s just cheaper to sell another brand and it’s 
wrong. That’s why people get mixed up - sometimes I know I 
do 
? No change as my doctor had written and advised me it was 
the same formula under a new name, but colour changes are 
confusing 
? If licenses are granted to several pharmaceutical companies 
could conformity of appearance be put into the contract? 
? Sometimes my blood pressure tablets are not written in 
English on the calendar pack. It helps at my age to know that 
I have missed any 
? Sometimes the foil covering the tablets is very thick which 
makes it difficult to press out and the tablets break 
? It would be much better if the respective tablets and 
packaging could be standardised irrespective of who 
manufactures them - otherwise if care is not taken, the wrong 
tablets could be taken at the wrong time 
? Pharmacist, 2 different size tablets in one bottle, sought 
advice was told a different supplier but there was no label 
attached or any verbal information before I sought advice 
? To change things just to save a few pence is not always a 
good thing to do. People’s lives come first 
? Medication labels in patient’s ethnic language would be very 
helpful. I appreciate this would be costly but it would enable 
me to regain confidence and independence while also being 
sure that I am taking the right dose at the right time when no-
one is available to help me 
? Pharmaceutical purchasing officers should be made aware of 
the difficulties caused for the patient when packaging 
specifications vary 
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? I would definitely prefer my medicines to be all the same 
brand 
? Perhaps explanation of any changes might be given by the 
pharmacist to alleviate or allay any worry someone might feel 
if unable to read or understand why the appearance of 
medication had changed 
? Tablets and packaging for older people should be kept the 
same  
? Labelling should be in bigger writing and clearer e.g. faint ink 
from printer 
? The name of the manufacturer was important to me - I felt 
that the quality and effectiveness of the drug was superior to 
the one made by the little known drug companies 
? Gets very confusing. Would be better if there were standards 
across all drug companies to keep each named drug same 
colour, size and shape and recognisable packaging 
? I wish we could have an MOT (like a car) once a year to 
check how our tablets are working for us 
? Whilst I am totally in control of my faculties I can imagine that 
these changes may be traumatic to some people 
? We should have a choice between bottles or foils 
? Very small print on packages and leaflets can be barely 
readable even with a magnifying glass. Also inadequate 
colour contrast on leaflets etc i.e. dark blue print on pale blue 
background; yellow on green etc 
? A warning sticker may be the answer just confirming the 
‘look’ of the tablet may have changed but the content is the 
same 
 
Large numbers of respondents suggested standardisation of tablet 
appearance. Many others indicated problems with foil packaging. 
 
 
Conclusions 
 
This is a modest yet valuable survey. It is noted that the views of 
those who did not respond may differ from those that did. What is 
of concern is whether there exists a higher level of negative 
experiences amongst those non-responders, some of whom may 
have been less able to participate and may also be less able to 
manage any medication appearance changes. We also accept that 
we have relied on the recollections of respondents, some of whom 
may not have recalled their experiences with accuracy. Some of 
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the changes in appearance noted may have been due to other 
reasons than generic prescribing or parallel import practices such 
as changes in dose.   
 
What is of more importance to those older people who have 
prompted the study is that a voice has been given to at least some 
of their peers to articulate the problems as they see them with 
regards to changed tablet medication appearance. Evidence that a 
problem exists for many - anxiety, poor medicines management, 
upset, confusion - has been uncovered which will add to a very 
limited existing evidence base. This will go some way to inform 
future research such as our own study starting in 2009 which will 
employ video-taped interviews of older people sharing their 
experiences of changed medication appearance. Collectively we 
hope all these findings will prompt substantive research into what 
we now believe is a widespread problem.  
 
Of immediate concern to those who develop policy or provide 
healthcare services should be that these findings clearly show that 
some older people are being put at risk due to changed medication 
appearance. Whilst medicines management has especially been 
invested in during recent years by organisations such as Primary 
Care Trusts, we suggest a closer look is taken at the extent and 
nature of the key aspect of medicines management that these 
findings highlight, namely managing changes in appearance. 
Perhaps pharmacy monitoring systems need to be revised (or 
developed where they do not exist) to establish the number and 
nature of changes to individuals’ medication appearance and to 
use this information to make decisions about which patients are 
best able to cope with medicines of altered appearance. The 
implications for the roles of those who prescribe or dispense 
medicines, or those who have caring responsibilities for older 
people such as district nurses, need to be considered. The widely 
reported good practice of pharmacists who have helped many 
respondents by sticking to a certain medication brand if the patient 
requests it and for allaying anxiety by providing support and advice 
regarding appearance changes, is to be praised and reinforced. 
Awareness raising and education for health care professionals 
could help them to help and educate older people to manage 
medicines that change appearance more effectively.  
 
Others would need to establish the cost implications of adjusting 
the current approaches of generic prescribing and parallel imports 
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to avoid their use with those patients at most risk of making 
mistakes. This study is clearly too small and of too limited a focus 
to recommend adjustments to these practices. What we have 
shown is that risk and harm is being experienced by unacceptable 
numbers of older people, which may be the tip of the iceberg and 
that the remainder of the iceberg should be explored substantively. 
Meanwhile the existing known risk needs addressing.      
 
 
Recommendations: 
 
• Ways need to be sought to manage the known risk and harm 
being experienced by some older people when faced with 
changed medication appearance 
 
• Means of educating healthcare professionals to support older 
people at most risk to better manage their medicines with 
regards to changed appearance need to be developed 
 
Future audit or research is needed to: 
 
• Explore the extent of the problems identified here amongst 
the wider older population including those who are less able 
to participate e.g. seldom heard or marginalised groups, 
those who are socially isolated etc 
 
• Monitor medicines with changed appearance that are 
dispensed to establish the nature, frequency and extent of 
changes for individuals as well as the profiles of those they 
are dispensed to  
 
• Establish the cost and quality of life implications of supplying 
generic medicines or parallel imports amongst vulnerable 
older adults 
 
 
